About
Allogeneic Cell Therapy Platform
Sakura Bio has developed an off-the-shelf, naïve PBMC-derived allogeneic T-cell therapy to fight cancer — in particular, acute myeloid leukemia.
The company's platform focuses on creating super-activated killer cells, an allogenic T-cell therapy produced via a simple, relatively short manipulation of naïve PBMCs.
Sakura Bio's lead product, Super Activated Killer T-cell (SAK-T), is a unique T-cell population with superior anti-tumor cytotoxic activity and no toxicity of healthy tissue. In contrast to other T-cell-based products, such as CAR-T, SAK-T cells have a high safety profile, with no graft-versus-host disease, and can be developed as an off-the-shelf T-cell product.
SAK-T's outstanding killing properties of leukemic cells led Sakura to choose acute myeloid leukemia as its first-in-human indication for SAK therapy.
Identity
| Name | Sakura Bio |
|---|---|
| Slug | sakura-bio |
| Type / kind | startup |
| Source _id | qOnuPo9oFdFJ0ajPABNJp3yUmMy0NBXNx1W1EOAIDWugobTSQRgDg0 |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Jerusalem |
| HQ address | Jerusalem, Israel |
Web & social
| Website | https://www.sakurabio.com/ |
|---|---|
| https://www.linkedin.com/company/86832778 |
Classifications
Funding
| Total raised | $1.7M |
|---|---|
| Current stage | Pre-Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}